Australia - engleză - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: polysorbate 80; iron oxide red; methacrylic acid - ethyl acrylate copolymer (1:1); maize starch; light magnesium oxide; povidone; glyceryl monostearate; macrogol 6000; hypromellose phthalate; purified talc; microcrystalline cellulose; pregelatinised maize starch; sucrose; hyprolose; silicon dioxide; crospovidone; macrogol 400; titanium dioxide; hypromellose - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - engleză - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: polysorbate 80; iron oxide red; methacrylic acid - ethyl acrylate copolymer (1:1); maize starch; light magnesium oxide; povidone; glyceryl monostearate; macrogol 6000; hypromellose phthalate; purified talc; microcrystalline cellulose; pregelatinised maize starch; sucrose; hyprolose; silicon dioxide; crospovidone; macrogol 400; titanium dioxide; hypromellose - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - engleză - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; glyceryl monostearate; microcrystalline cellulose; silicon dioxide; crospovidone; polysorbate 80; macrogol 6000; pregelatinised maize starch; iron oxide red; maize starch; light magnesium oxide; povidone; sucrose; hyprolose; hypromellose phthalate; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - engleză - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; hypromellose phthalate; glyceryl monostearate; microcrystalline cellulose; silicon dioxide; crospovidone; polysorbate 80; macrogol 6000; pregelatinised maize starch; iron oxide red; maize starch; light magnesium oxide; povidone; sucrose; hyprolose; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - engleză - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: polysorbate 80; silicon dioxide; sucrose; purified talc; crospovidone; macrogol 6000; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); microcrystalline cellulose; iron oxide red; light magnesium oxide; hypromellose phthalate; povidone; pregelatinised maize starch; glyceryl monostearate; maize starch; macrogol 400; titanium dioxide; hypromellose - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - engleză - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty mg) - tablet, enteric coated - excipient ingredients: crospovidone; hypromellose phthalate; polysorbate 80; purified talc; hyprolose; macrogol 6000; povidone; sucrose; silicon dioxide; maize starch; glyceryl monostearate; iron oxide red; pregelatinised maize starch; methacrylic acid - ethyl acrylate copolymer (1:1); microcrystalline cellulose; light magnesium oxide; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - engleză - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium, quantity: 22.264 mg (equivalent: esomeprazole, qty mg) - tablet, enteric coated - excipient ingredients: purified water; purified talc; lactose monohydrate; crospovidone; light magnesium oxide; macrogol 400; hyprolose; macrogol 6000; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; silicon dioxide; iron oxide red; pregelatinised maize starch; povidone; microcrystalline cellulose; hypromellose phthalate; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - engleză - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium, quantity: 44.528 mg (equivalent: esomeprazole, qty mg) - tablet, enteric coated - excipient ingredients: polysorbate 80; hypromellose phthalate; pregelatinised maize starch; macrogol 6000; light magnesium oxide; purified water; povidone; glyceryl monostearate; silicon dioxide; microcrystalline cellulose; crospovidone; macrogol 400; purified talc; iron oxide red; lactose monohydrate; methacrylic acid - ethyl acrylate copolymer (1:1); hyprolose; titanium dioxide; hypromellose; maize starch; sucrose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - engleză - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified water; glyceryl monostearate; povidone; macrogol 400; macrogol 6000; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose phthalate; iron oxide red; microcrystalline cellulose; silicon dioxide; polysorbate 80; light magnesium oxide; purified talc; pregelatinised maize starch; crospovidone; maize starch; sucrose; titanium dioxide; hypromellose; iron oxide yellow - for the symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hyprolose; sucrose; iron oxide red; glyceryl monostearate; polysorbate 80; povidone; light magnesium oxide; purified talc; crospovidone; pregelatinised maize starch; macrogol 400; hypromellose phthalate; maize starch; silicon dioxide; macrogol 6000; methacrylic acid - ethyl acrylate copolymer (1:1); microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for:,? healing of